home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Adverse Drug Events – Reporting & Regulatory Requirements

 
  June 04, 2007  
     
 
The Center for Professional Innovation & Education, Malvern, PA
12/13/07


Who Should Attend

This two-day course is designed for those involved with Clinical Research, Safety Surveillance, Regulatory Affairs, Clinical Trials, Medical Affairs and QA/QC issues. It will also benefit Audit personnel and those in management who require a full understanding of adverse event reporting and regulations.

Learning Objectives

During this two day course you will learn about:

-FDA’s role in the drug development process
-The clinical research process
-Pharmacovigilance
-Adverse events (expected and unexpected)
-Safety issues
-Coding
-Safety issues in investigational studies
-Safety issues in the post-marketing era


Course Description

This course will provide participants an understanding of drug safety at the investigational stage and during the marketing phase. Adverse event identification and reporting requirements will be addressed. FDA/ICH roles in the drug safety process will be reviewed. The course will also discuss FDA law/regulations, ICH guidelines, Pharmacovigilance, definitions and current regulatory issues.


 
 
Organized by: Center for Professional Innovation & Education
Invited Speakers: Please contact The Center for Professional Innovation & Education at info@cfpie.com or call +1-610-688-1708 for Speaker information.
 
Deadline for Abstracts: n/a
 
Registration: To Register, please visit www.cfpie.com or call +1-610-688-1708
E-mail: info@cfpie.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.